Back4d Pharma Plc - Warrants (22/02/2025) Overview

4d Pharma Plc - Warrants (22/02/2025) Net Tangible Assets

Latest net tangible assets for LBPSW: $32M.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$32.42M
15.90% YoYΔ $4.45M vs prior year quarter

Peer average / median

Loading

4d Pharma Plc - Warrants (22/02/2025) Net Tangible Assets History

Loading

4d Pharma Plc - Warrants (22/02/2025) vs. peers: Net Tangible Assets Comparison

Loading

4d Pharma Plc - Warrants (22/02/2025) Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

4d Pharma Plc - Warrants (22/02/2025) (LBPSW) FAQ

As of the most recent data (December 2021), LBPSW shows a net tangible assets of $32M. That compares with $28M in the prior-year period — up 15.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, LBPSW's net tangible assets is now $32M (was $28M) — a 15.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether 4d Pharma Plc - Warrants (22/02/2025) is outperforming or lagging.

Tracking LBPSW's net tangible assets over time shows whether 4d Pharma Plc - Warrants (22/02/2025) is scaling, shrinking, or reshaping that part of the business. The current reading is $32M That compares with $28M in the prior-year period — up 15.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net tangible assets page, Stockcircle has 4d Pharma Plc - Warrants (22/02/2025)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $32M) with ownership activity and broader fundamentals.

4d Pharma Plc - Warrants (22/02/2025)'s net tangible assets is $32M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.